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Abstract
Background: Di-(2-ethylhexyl)phthalate (DEHP) is a common endocrine disrupting compound (EDC) present in the
environment as a result of industrial activity and leaching from polyvinyl products. DEHP is used as a plasticizer in
medical devices and many commercial and household items. Exposure occurs through inhalation, ingestion, and
skin contact. DEHP is metabolized to a primary metabolite mono-(2-ethylhexyl)phthalate (MEHP) in the body, which
is further metabolized to four major secondary metabolites, mono(2-ethyl-5-hydroxyhexyl)phthalate (5-OH-MEHP),
mono(2-ethyl-5-oxyhexyl)phthalate (5-oxo-MEHP), mono(2-ethyl-5-carboxypentyl)phthalate (5-cx-MEPP) and
mono[2-(carboxymethyl)hexyl]phthalate (2-cx-MMHP). DEHP and its metabolites are associated with developmental
abnormalities and reproductive dysfunction within the human population. Progesterone receptor (PR) signaling is
involved in important reproductive functions and is a potential target for endocrine disrupting activities of DEHP and
its metabolites. This study used in silico approaches for structural binding analyses of DEHP and its five indicated major
metabolites with PR.
Methods: Protein Data bank was searched to retrieve the crystal structure of human PR (Id: 1SQN). PubChem database
was used to obtain the structures of DEHP and its five metabolites. Docking was performed using Glide (Schrodinger)
Induced Fit Docking module.
Results: DEHP and its metabolites interacted with 19-25 residues of PR with the majority of the interacting residues
overlapping (82-95 % commonality) with the native bound ligand norethindrone (NET). DEHP and each of its five
metabolites formed a hydrogen bonding interaction with residue Gln-725 of PR. The binding affinity was highest for
NET followed by DEHP, 5-OH-MEHP, 5-oxo-MEHP, MEHP, 5-cx-MEPP, and 2-cx-MMHP.
Conclusion: The high binding affinity of DEHP and its five major metabolites with PR as well as a high rate of overlap
between PR interacting residues among DEHP and its metabolites and the native ligand, NET, suggested their
disrupting potential in normal PR signaling, resulting in adverse reproductive effects.
Keywords: Docking, Progesterone receptor, DEHP, 5-OH-MEHP, 5-oxo-MEHP, MEHP, 5-cx-MEPP, 2-cx-MMHP
* Correspondence: mabeg51@gmail.com
1King Fahd Medical Research Center, King Abdulaziz University, PO Box
80216, Jeddah 21589, Kingdom of Saudi Arabia
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The Author(s) BMC Structural Biology 2016, 16(Suppl 1):16
DOI 10.1186/s12900-016-0066-4
Background
The chemical industry contributes significantly to the
prosperity and economic development of modern soci-
ety. However, many chemical compounds that are dis-
charged into the environment due to industrial activity
and leaching from consumer products interfere with the
physiological functions of the exposed human and ani-
mal populations and are referred to as endocrine dis-
rupting compounds (EDCs) [1–3].
Di-(2-ethylhexyl)phthalate (DEHP) is a high volume plas-
ticizer used as a softener in polyvinyl chloride industry with
a 54 % market share (2010 data) and is considered as one
of the most common EDCs present in the environment
[4]. DEHP is frequently used in the manufacture of medical
devices, blood storage bags, surgical gloves, dialysis
equipment, cosmetics, household and personal items such
as soap, shampoo, detergents, adhesives, vinyl flooring,
shower curtains, plastic bags, garden hoses, children’s toys,
and many other plastic products [4]. Exposure of human
population to DEHP occurs continuously through inhal-
ation, ingestion, and skin contact [5]. Recently [6], DEHP
was detected in 74 % of 72 common food items including
infant foods, chicken, pork and other food items in a mar-
ket in Albany, New York. DEHP is metabolized in the body
by hydrolysis to a primary metabolite, mono-(2-ethylhex-
yl)phthalate (MEHP), which is then further metabolized
into multiple hydroxylative and oxidative secondary
metabolites [7, 8]. The four major secondary metabolites of
DEHP are mono(2-ethyl-5-hydroxyhexyl)phthalate (5-
OH-MEHP), mono(2-ethyl-5-oxyhexyl)phthalate (5-oxo-
MEHP), mono(2-ethyl-5-carboxypentyl)phthalate (5-cx-
MEPP) and mono[2-(carboxymethyl)hexyl]phthalate (2-
cx-MMHP) [7, 8]. A simplified metabolic pathway of 5
major metabolites of DEHP is illustrated (Fig. 1).
DEHP and its metabolites have been detected in various
human body fluids such as blood and breast milk [9], fol-
licular fluid [10], amniotic fluid [11], cord blood of new-
borns [12] and urine [5] indicating immense potential for
adverse health effects. Monoester metabolites rather than
native DEHP are thought to be responsible for toxicity of
DEHP [13] with secondary metabolites displaying a 100
fold increase in embryo-toxicity compared to MEHP [14].
In a recent study [15], positive associations were reported
between total DEHP metabolites, MEHP, 5-OH-MEHP,
and 5-oxo-MEHP levels in urine and plasma estradiol and
ratio of estradiol to testosterone. Higher levels of MEHP,
5-OH-MEHP, and 5-oxo-MEHP were associated with
lower sperm concentration, lower sperm motility, higher
sperm apoptosis, and ROS generation [16]. Prenatal ex-
posure with DEHP and its metabolites has been associated
with reduced gestational age for pregnancies bearing male
fetus [17], anogenital distance problems in male babies
[18–20], cryptorchidism [21], altered reproductive hor-
mone levels [22], hypospadias [23], intellectual and motor
development in children [24], and preterm birth [25, 26].
Retrospective analyses of DEHP metabolites in pregnancy
Fig. 1 Two dimensional representation and a simplified pathway of di-(2-ethylhexyl)phthalate (DEHP) and its five major metabolites,
mono-(2-ethylhexyl)phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl)phthalate (5-OH-MEHP), mono-(2-ethyl-5-oxyhexyl)phthalate (5-oxo-MEHP),
mono-(2-ethyl-5-carboxypentyl)phthalate (5-cx-MEPP), and mono-[2-(carboxymethyl)hexyl]phthalate (2-cx-MMHP)
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serum of mothers [27] indicated that prenatal exposure of
children to DEHP was associated with reproductive prob-
lems during adolescence; higher 5-OH-MEHP level in
prenatal maternal serum was related with lower semen
volume and lower sperm concentrations and higher 5-cx-
MEPP was associated with lower free testosterone
concentrations.
Studies in rats and mice have also shown that exposure
to DEHP can induce deleterious reproductive and endo-
crine effects [28–31]. In rats, prenatal DEHP treatment
was associated with developmental abnormalities in male
pups such as cryptorchidism, anogenital problems, and
malformations of epididymis, vas deferens, seminal vesi-
cles, prostate, and external genitalia collectively called as
the phthalate syndrome, which is similar to effects of
DEHP exposure in men [32, 33]. In vitro, MEHP and 5-
OH-MEHP decreased gonocyte number and increased
gonocyte apoptosis in rat testis organ culture [34].
In general, EDCs have been proposed to exert their toxic
effects through interactions with nuclear steroid receptors,
sex steroid binding proteins, and steroid enzymatic path-
ways regulating reproductive and endocrine functions [1].
Progesterone receptor (PR) belongs to the family of nuclear
receptors and binds to progesterone, which is an important
hormone involved in female reproductive function and
maintenance of pregnancy [35, 36] as well as an important
modulator of male reproductive function [37]. Interference
in PR signaling leads to reproductive dysfunction and preg-
nancy failure [38]. Recently [39], docking studies of PR
with three stereoisomers of DEHP have been reported.
Docking of DEHP and its primary metabolite, MEHP, with
PR have also been reported [40], however, the important
secondary metabolites were not included in the study.
This study aimed at analyzing and comparing the
structural binding characteristics of DEHP and its five
major metabolites, MEHP, 5-OH-MEHP, 5-oxo-MEHP,
5-cx-MEPP, and 2-cx-MMHP with PR using in silico ap-
proaches. The study involved the delineation of the
binding mechanism of all the six xeno-ligands with PR
by molecular docking simulation and comparing the dis-
tinctive binding pattern and the interacting residues.
Methods
Data retrieval
The molecular structures of DEHP and its five major
metabolites, MEHP, 5-OH-MEHP, 5-oxo-MEHP, 5-cx-
MEPP, and 2-cx-MMHP were retrieved from PubChem
compound database. The two dimensional structures of
the ligands are illustrated (Fig. 1) and their abbreviations
and PubChem compound identities (CIDs) are presented
(Table 1). Schrodinger 2015 suite with Maestro 10.3
(graphical user interface) software (Schrodinger, LLC,
New York, NY, 2015) was used for docking studies of
DEHP and its five metabolites [39].
Protein selection and preparation
The Protein Data Bank (PDB; http://www.rcsb.org/) was
searched to retrieve the crystal structure of human PR
(PDB code: 1SQN) with a resolution of 1.45 Å. The crys-
tal structure was a co-complex with bound ligand, nor-
ethindrone (NET). The preparation of the co-complex
crystal structure for docking analysis was done using
protein preparation wizard workflow of Schrodinger
Glide (Schrodinger suite 2015-3; Schrodinger, LLC) and
was described in detail [39]. Briefly, the PDB structure
was imported to docking software Glide and using pro-
tein preparation wizard workflow, OPLS-2005 force
field, and Prime 3.0 module software water molecules
were removed, hydrogen atoms and charges were added,
and loops and missing side chains were built. The
hydrogen bonding network was optimized and finally a
geometry optimization was performed to a maximum
root-mean-square deviation (RMSD) of 0.30 Å. For gen-
erating grid boxes, bound ligand (NET) in crystal com-
plex was selected and used for docking of DEHP and its
five metabolites.
Ligand preparation, conformational search
The methodology described above [39] was employed to
draw ligand structures (Fig. 1) using Maestro 10.3
(Maestro, version 10.3, Schrodinger, LLC). LigPrep module
(Schrodinger 2015: LigPrep, version 3.1, Schrodinger, LLC)
was used for preparation of ligands and correct molecular
Table 1 Nomenclature, commonly used abbreviations, and PubChem IDs of di-(2-ethylhexyl)phthalate and its five major metabolites
for docking study with human progesterone receptor (PR)
S.No. Name Abbreviation PubChem ID
1 Di-(2-ethylhexyl)phthalate DEHP 8343
2 Mono-(2-ethylhexyl)phthalate MEHP 20393
3 Mono-(2-ethyl-5-hydroxyhexyl)phthalate 5-OH-MEHP 170295
4 Mono-(2-ethyl-5-oxyhexyl)phthalate 5-oxo-MEHP 119096
5 Mono-(2-ethyl-5-carboxypentyl)phthalate 5-cx-MEPP 149386
6 Mono-[2-(carboxymethyl)hexyl]phthalate 2-cx-MMHP 187353
7 Norethindrone NET 6230
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geometries and ionization at biological pH 7.4 were ob-
tained by using the OPLS-2005 force field software.
Induced fit docking
Schrodinger’s Induced Fit Docking (IFD) module was
used for docking analyses of the DEHP and its five
metabolites MEHP, 5-OH-MEHP, 5-oxo-MEHP, 5-cx-
MEPP, and 2-cx-MMHP [39]. The ligands were submit-
ted as starting geometries to IFD which is capable of
sampling the minor changes in the backbone structure
as well as robust conformational changes in side chains
[41]. A softened-potential docking is performed in the
first IFD stage where docking of the ligand occurs into
an ensemble of the binding protein conformations. Sub-
sequently, complex minimization for highest ranked
pose is performed where both ligand and binding sites
are free to move.
Binding energy calculations
The ligand binding affinity calculations against the
crystal complex was executed using Prime module of
Schrodinger 2015 with MMGB-SA function.
Results
Successful execution of IFD for docking simulation of
DEHP and its five major metabolites, MEHP, 5-OH-
MEHP, 5-oxo-MEHP, 5-cx-MEPP, and 2-cx-MMHP
against the ligand binding pocket of PR resulted in mul-
tiple docking poses for each ligand. The best pose for
each ligand was analyzed further for in silico data con-
siderations and the resulting data is presented here
(Figs. 2, 3, 4, 5, 6 and 7). Similarly, for the co-complex
bound ligand (NET) of PR the data for the best pose
after IFD are illustrated (Fig. 8).
Docking complexes of DEHP and its five major metab-
olites, MEHP, 5-OH-MEHP, 5-oxo-MEHP, 5-cx-MEPP,
and 2-cx-MMHP displayed interactions with 19-25
amino acid residues of PR (Figs. 2, 3, 4, 5, 6 and 7,
Table 2). The bound ligand, NET, displayed interactions
with 22 residues of PR in the NET-PR docking complex
(Fig. 8; Table 2). DEHP and its five metabolites shared
18-21 PR interacting residues with the bound native PR lig-
and, NET, (commonality of 82-95 %; Table 2). For each of
the native ligand, NET, and DEHP and its five metabolites,
16 PR interacting residues (Leu-718, Asn-719, Leu-721,
Gln-725, Met-756, Met-759, Val-760, Leu-763, Arg-766,
Phe-778, Leu-797, Met-801, Leu-887, Tyr-890, Cys-891,
Met-909) were common (Table 3). The PR interacting res-
idues, Leu-715 and Thr-894 were also common between
bound ligand, NET, and DEHP and all of its metabolites
except MEHP, and residue Gly-722 was common between
NET and all ligands except 5-OH-MEHP (Table 3). In
addition, two residues, Trp-755 and Phe-905 were
common among NET and 4 of 6 ligand molecules (not
shown). DEHP and each of its five metabolites and bound
native ligand, NET, formed a hydrogen bonding inter-
action against residue Gln-725 of PR. In addition, MEHP,
5-oxo-MEHP, 5-cx-MEPP, and 2-cx-MMHP each formed
two hydrogen bonding interactions with residue Arg-766
of PR. The metabolite 5-OH-MEHP formed only one
hydrogen bonding interaction with Arg-766 but was also
involved in a hydrogen bonding interaction with another
residue, Asn-719, of PR. The IFD score, Dock score, and
Glide score for all the docked xeno-ligands and bound
native ligand, NET, are presented (Table 2). The binding
affinity values (MMGB-SA values) were highest for NET
followed by DEHP, 5-OH-MEHP, 5-oxo-MEHP, MEHP,
5-cx-MEPP, and 2-cx-MMHP (Table 2).
Discussion
Di-(2-ethylhexyl)phthalate (DEHP) is a widely used
phthalate compound representing more than half of all
phthalate compounds manufactured worldwide for use
in the industry as a plasticizer. Several reviews showed
Fig. 2 Ribbon form representation of docking complex of human progesterone receptor (PR) with di-(2-ethylhexyl)phthalate (DEHP) (left panel).
Amino-acid residues in the binding pocket of PR involved in interactions with DEHP (right panel)
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that DEHP is a universally prevalent environmental con-
taminant and behaves as a reproductive and develop-
mental toxin [5, 28, 29, 32, 42]. Several epidemiological
reports have identified DEHP and its metabolites as the
cause of adverse effects on various systems of the body in-
cluding endocrine and reproductive system [28, 29, 32].
Many studies have reported developmental problems dur-
ing prenatal period and postnatal period in unborn and
new born children as a result of gestational exposure of
mothers to DEHP [18–20, 24, 42, 43]. In women, higher
urinary or serum levels of DEHP and its metabolites were
associated with problems in conception, endometriosis,
and high rates of miscarriage, delayed or preterm gesta-
tion, and pregnancy associated toxemia and preeclampsia
[25, 26, 28, 29]. In men, higher urinary or serum levels of
DEHP and its metabolites were linked with lower semen
volume, lower sperm concentrations, lower sperm motil-
ity, higher sperm apoptosis, and lower testosterone
concentrations [5, 16, 27, 32, 44, 45]. Due to side effects of
DEHP mentioned above, it has been banned since 2009 in
the United States for use in children’s toys and the
European Union has also classified DEHP as a repro-
ductive toxicant. However, DEHP continues to be manu-
factured and used in many countries across the world.
DEHP is metabolized in the body by hydroxylative and
oxidative reactions to many metabolic products which
include five major metabolites: MEHP, 5-OH-MEHP,
5-oxo-MEHP, 5-cx-MEPP, and 2-cx-MMHP ([7, 8]; see
Introduction section). The toxicity of DEHP in the body is
attributed mainly to the actions of its secondary metabo-
lites [13, 14]. Progesterone receptor signaling is an
essential pathway controlling reproductive function and is
involved in reproductive periodicity and establishment
and maintenance of pregnancy [35, 36]. DEHP and the
indicated five major metabolites can act as potential xeno-
ligands for PR and disrupt the normal progesterone
Fig. 3 Ribbon form representation of docking complex of human progesterone receptor (PR) with mono-(2-ethylhexyl)phthalate (MEHP) (left panel).
Amino-acid residues in the binding pocket of PR involved in interactions with MEHP (right panel)
Fig. 4 Ribbon form representation of docking complex of human progesterone receptor (PR) with mono-(2-ethyl-5-hydroxyhexyl)phthalate
(5-OH-MEHP) (left panel). Amino-acid residues in the binding pocket of PR involved in interactions with 5-OH-MEHP (right panel)
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signaling pathway and this could be one of the important
mechanisms which lead to adverse effects in the human
population. In the present study, docking simulations of
DEHP and its five major metabolites namely, MEHP,
5-OH-MEHP, 5-oxo-MEHP, 5-cx-MEPP, and 2-cx-
MMHP were performed with PR and comparison of
docking displays and interacting residues was performed
among the ligands and the co-complex bound native
ligand, norethindrone (NET) of PR crystal structure.
Induced Fit Docking of DEHP and its five metabolites
with PR showed that all the six xeno-ligands fitted well
into the steroid binding pocket of the receptor. The high
binding affinity values, IFD scores, and dock scores indi-
cated that the docking complexes formed by DEHP,
MEHP, 5-OH-MEHP, 5-oxo-MEHP, 5-cx-MEPP, and
2-cx-MMHP with PR were in their most favorable con-
formation. A number of important PR amino acid residues
interacted through hydrophobic and hydrogen-bonding
interfaces with each of the six xeno-ligands during
docking simulation contributing to the ligand-PR docking
complex stability. A consistent and high overlapping
(82-95 % commonality) of the interacting residues of PR
among native bound ligand, NET, and DEHP and its
metabolites suggested a common platform of action. This
was further supported by the fact that 16 of the 22 PR res-
idues interacting with bound native ligand, NET, also
interacted with DEHP and each of the five metabolites. In
addition, DEHP and each of its five metabolites, and
bound native ligand, NET, formed a hydrogen bonding
interaction against residue Gln-725 of PR altogether
pointing to the common structural binding characteristics
of the native bound ligand and the six xeno-ligands. Com-
monality of structural binding characteristics of bound
native ligand, NET, and DEHP and its metabolites with PR
suggest, on a preliminary basis, potential disruption of PR
function by DEHP and its metabolites.
Fig. 5 Ribbon form representation of docking complex of human progesterone receptor (PR) with mono-(2-ethyl-5-oxyhexyl)phthalate (5-oxo-MEHP)
(left panel). Amino-acid residues in the binding pocket of PR involved in interactions with 5-oxo-MEHP (right panel)
Fig. 6 Ribbon form representation of docking complex of human progesterone receptor (PR) with mono-(2-ethyl-5-carboxypentyl)phthalate
(5-cx-MEPP) (left panel). Amino-acid residues in the binding pocket of PR involved in interactions with 5-cx-MEPP (right panel)
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To the best of our knowledge, the current study is the
first structure based report for docking stimulation of
secondary metabolites of DEHP with PR. In vitro com-
petitive binding of DEHP and its metabolites with PR
are seemingly unavailable. Docking studies of PR with
three stereoisomers of DEHP have recently been re-
ported [39]. Docking of DEHP and its primary metabol-
ite, MEHP, with PR have also been reported [40]. The
results of the current study with docking of DEHP and
PR support the results of the reported study [40] show-
ing residues Gln-725, Arg-766 and Phe-778 as the cru-
cial interacting residues of PR interaction with DEHP.
The importance of the current study lies in the fact that
the secondary metabolites of DEHP viz. 5-OH-MEHP, 5-
oxo-MEHP, 5-cx-MEPP, and 2-cx-MMHP are the best
biomonitoring markers of DEHP in the urine or blood
and are potentially more potent disruptors because of
their long elimination half-life compared to the primary
metabolite, MEHP [7, 8]. Approximately 75 % of a single
dose of DEHP was excreted in urine within two days;
67 % was excreted within the first 24 h which included
6 % MEHP, 23 % 5-OH-MEHP, 15 % 5-oxo-MEHP, 19 %
5-cx-MEPP, and 4 % 2-cx-MMHP (Koch et al. [8]). Of
the 3.8 % excreted in the next 24 h, more than 75 %
included 5-cx-MEPP and 2-cx-MMHP and the rest
included 5-OH-MEHP and 5-oxo-MEHP indicating
long elimination half-lives of the former two secondary
metabolites.
Although not related to the progesterone receptor,
DEHP treatment inhibited progesterone secretion from
human luteal cells in culture [46]. Furthermore, in vivo
treatment of DEHP decreased secretion of progesterone
in mice [47] and in vitro treatment of MA-10 mouse
Leydig cells with MEHP resulted in inhibition of
steroidogenesis including progesterone secretion [48].
Interestingly, in sheep, DEHP causes shortening of
Fig. 7 Ribbon form representation of docking complex of human progesterone receptor (PR) with mono-[2-(carboxymethyl)hexyl]phthalate
(2-cx-MMHP)(left panel). Amino-acid residues in the binding pocket of PR involved in interactions with 2-cx-MMHP (right panel)
Fig. 8 Ribbon form representation of docking complex of human progesterone receptor (PR) with native co-complex ligand norethindrone (NET)
(left panel). Amino-acid residues in the binding pocket of PR involved in interactions with NET (right panel)
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estrous cycles due to a reduction in the size and lifespan
of CL, however, in contrast to mice, an increase in circu-
lating concentrations of progesterone was noted [49].
Conversely, MEHP treatment was associated with an in-
crease in steroidogenesis including progesterone concen-
trations in cultured rat ovarian follicles [50]. Apparently,
direct studies involving treatments with secondary me-
tabolite compounds namely 5-OH-MEHP, 5-oxo-MEHP,
5-cx-MEPP, and 2-cx-MMHP in laboratory animals or in
in vitro cell cultures are not available. It goes without say-
ing that no single mechanism or pathway can explain the
endocrine disrupting effects of DEHP and its metabolites
on reproductive and endocrine systems in the human
body. As an example, PPAR alpha was thought to be a
possible pathway of adverse effects of DEHP in mice, how-
ever, the toxic effects were observed despite the use of
PPAR alpha null mice suggesting the involvement of add-
itional pathways [51]. Besides the PR signaling pathway,
multiple other pathways could mediate the adverse effects
of DEHP and its metabolites in the body. Androgen recep-
tor pathway could also be an important mechanism as
agonistic (androgenic) and antagonistic (antiandrogenic)
actions of DEHP and other phthalate compounds have
been shown at the androgen receptor level [52]. This
study showed that DEHP and all its five major metabolites
were able to bind to PR with structural binding character-
istics that were common with the bound native ligand,
NET, of PR. Hence, DEHP and its five metabolites have
potential to interfere with the binding of progesterone to
its receptor resulting in adverse effects and the dysfunc-
tion of progesterone signaling.
Conclusion
This study was undertaken to understand the structural
binding mechanisms of DEHP and its five major metab-
olites (MEHP, 5-OH-MEHP, 5-oxo-MEHP, 5-cx-MEPP,
and 2-cx-MMHP) with PR in order to predict their po-
tential adverse effects on progesterone signaling. The re-
sults indicated, a high percentage of overlap (82-95 %)
among the interacting residues of PR for the native
bound ligand, NET, and for DEHP and its metabolites.
The structural binding similarities were further sup-
ported by a common hydrogen bonding interaction be-
tween Gln-725 residue of PR and DEHP,each of its five
metabolites, and bound native ligand, NET. Therefore,
on a preliminary basis, the six xeno-ligands have poten-
tial disruptive activities in the binding of progesterone to
its receptor resulting in the dysfunction of progesterone
signaling and adverse effects.
Table 2 Number of interacting residues, number and percentage of residues common with native ligand norethindrone (NET),
Induced Fit Docking (IFD) Score, Dock score, Glide score and binding affinity values (MMGB-SA values) of di-(2-ethylhexyl)phthalate
(DEHP), mono-(2-ethylhexyl)phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl)phthalate (5-OH-MEHP), mono-(2-ethyl-5-oxyhexyl)phthalate
(5-oxo-MEHP), mono-(2-ethyl-5-carboxypentyl)phthalate (5-cx-MEPP), and mono-[2-(carboxymethyl)hexyl]phthalate (2-cx-MMHP) and native
co-complex ligand, NET, after IDF with human progesterone receptor (PR)
S. no. Ligand Number of interacting
residues
Number of interacting residues
common with NET (%)






1 DEHP 25 20 (91 %) -563.15 -9.59 -9.59 -131.26
2 MEHP 19 18 (82 %) -560.47 -8.40 -8.40 -84.18
3 5-OH-MEHP 22 20 (91 %) -561.24 -8.95 -8.95 -90.78
4 5-oxo-MEHP 22 20 (91 %) -561.72 -8.83 -8.83 -87.24
5 5-cx-MEPP 21 21 (95 %) -562.87 -10.52 -10.52 -80.01
6 2-cx-MMHP 24 21 (95 %) -562.01 -9.02 -9.02 -68.59
7 NET 22 22 (100 %) -566.25 -12.13 -12.13 -139.00
Table 3 Amino-acid residues of human progesterone receptor that
were common among co-complex natural ligand, norethindrone
(NET), and di-(2-ethylhexyl)phthalate (DEHP) and its five major
metabolites, mono-(2-ethylhexyl)phthalate (MEHP), mono-
(2-ethyl-5-hydroxyhexyl)phthalate (5-OH-MEHP), mono-(2-ethyl-
5-oxyhexyl)phthalate (5-oxo-MEHP), mono-(2-ethyl-5-
carboxypentyl)phthalate (5-cx-MEPP), and mono-[2-(carboxymethyl)-
hexyl]phthalate (2-cx-MMHP)
S. no Interacting residue S. no Interacting residue
1 Leu-715a 12 Phe-778
2 Leu-718 13 Leu-797
3 Asn-719 14 Met-801
4 Leu-721 15 Leu-887
5 Gly-722b 16 Tyr-890
6 Gln-725 17 Cys-891
7 Met-756 18 Thr-894a




Amino-acid residues indicated by superscript a were not shared by MEHP and
the residue indicated by superscript b was not shared by 5-OH-MEHP
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